CelLBxHealth
CelLBxHealth is a Guildford-based liquid biopsy company that develops and manufactures microfluidic circulating tumour cell harvesting technology and provides associated laboratory services.
Its FDA-cleared instrument captures intact circulating tumour cells from blood samples for downstream genomic, transcriptomic, and proteomic analysis.
The company serves pharmaceutical companies conducting oncology clinical trials and research laboratories studying cancer biology, and operates GCP-compliant clinical service laboratories in the UK and the United States.
Latest News
CelLBxHealth Cuts Nine-Month Cash Operating Loss 60% and Targets £3-4M Revenue in 2027
CelLBxHealth has cut its nine-month cash operating loss by 60% to £4.0 million and expects FY26 revenue of about £1.8 million, up 29%, with a target of £3 to 4 million for 2027. The company says existing resources and an expected R&D tax credit extend its cash runway into Q1 2027.
CelLBxHealth's Parsortix Platform Validated for ADC Target Detection
A peer-reviewed study by researchers at Trinity College Dublin and St James's Hospital has shown CelLBxHealth's Parsortix platform can detect antibody-drug conjugate targets, including TROP-2 and FRα, on circulating tumour cells from triple-negative breast cancer and ovarian cancer patients. The platform detected these targets even on tumour cells with low EpCAM expression, which many conventional capture methods miss, supporting its use in monitoring the $17bn global ADC drug market.